Michael Bitar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Bitar has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Andreas Boldt
Institute of Clinical Immunology, Medical Faculty University of Leipzig Leipzig Germany
3 shared publicationsUlrich Sack
Institute of Clinical Immunology, Medical Faculty University of Leipzig Leipzig Germany
3 shared publicationsUlrike Köhl
Institute of Clinical Immunology, Medical Faculty University of Leipzig Leipzig Germany
2 shared publicationsBernd Gruhn
Department of Pediatrics, Jena University Hospital, Jena, Germany
1 shared publicationFabian Hauck
Department of Pediatrics, Dr. von Hauner Children's Hospital University Hospital, Ludwig‐Maximilians‐University of Munich Munich Germany
1 shared publicationKarim Kentouche
Department of Pediatrics, Jena University Hospital, Jena, Germany
1 shared publication
Latest Publications
- Open Access
- 6 December 2020
- Published by Wiley in Cytometry Part A
- Vol. 99 (8) , 774-783
Flow cytometric measurement of STAT5 phosphorylation in cytomegalovirus‐stimulated T cells
Cytomegalovirus (CMV)‐specific T cells expand with CMV reactivation and are probably prerequisite for control and protection. Given the critical role STAT5A phosphorylation (pSTAT5A) in T cell proliferation, this study presents a simple and sensitive flow cytometric‐based pSTAT5A assay to quickly identify CMV‐specific T cell proliferation. We determined pSTAT5A in T cells treated with CMV‐specific peptide mix (pp65 + IE1 peptides) from 20 healthy adult subjects and three immunodeficient patients with CARMIL‐2 mutation. After stimulation, the percentage of pSTAT5A+ T cells in CMV‐seropositive (CMV+) subjects significantly increased from 3.0% ± 1.9% (unstimulated) to 11.4% ± 5.9% (stimulated) for 24 h. After 7 days of stimulation, the percentage of expanded T cells amounted to 26% ± 17.2%. Conversely, the percentage of pSTAT5A+ T cells and T cell proliferation from CMV‐seronegative (CMV−) subjects hardly changed (from 3.0% ± 1.3% to 3.7% ± 1.8% and from 4.3% ± 2.1% to 5.7% ± 1.7%, respectively). We analyzed the correlation between the percentage of pSTAT5A+ T cells versus (1) CMV‐IgG concentrations versus (2) the percentage of expanded T cells and versus (3) the percentage of initial CMV‐specific T cells. In immunodeficient patients with CARMIL‐2 mutation, CMV‐specific pSTAT5A and T cell proliferation were completely deficient. In conclusion, flow cytometric‐based pSTAT5A assay represents an appropriate tool to quickly identify CMV‐specific T cell proliferation and helps to understand dysfunctions in controlling other pathogens. Flow cytometric‐based pSTAT5A assay may be a useful test in clinical practice and merits further validation in large studies.
- 6 December 2020
- Published by Wiley in Cytometry Part A
- Vol. 99 (8) , 774-783
Open AccessFlow cytometric measurement of STAT5 phosphorylation in cytomegalovirus‐stimulated T cells
Cytomegalovirus (CMV)‐specific T cells expand with CMV reactivation and are probably prerequisite for control and protection. Given the critical role STAT5A phosphorylation (pSTAT5A) in T cell proliferation, this study presents a simple and sensitive flow cytometric‐based pSTAT5A assay to quickly identify CMV‐specific T cell proliferation. We determined pSTAT5A in T cells treated with CMV‐specific peptide mix (pp65 + IE1 peptides) from 20 healthy adult subjects and three immunodeficient patients with CARMIL‐2 mutation. After stimulation, the percentage of pSTAT5A+ T cells in CMV‐seropositive (CMV+) subjects significantly increased from 3.0% ± 1.9% (unstimulated) to 11.4% ± 5.9% (stimulated) for 24 h. After 7 days of stimulation, the percentage of expanded T cells amounted to 26% ± 17.2%. Conversely, the percentage of pSTAT5A+ T cells and T cell proliferation from CMV‐seronegative (CMV−) subjects hardly changed (from 3.0% ± 1.3% to 3.7% ± 1.8% and from 4.3% ± 2.1% to 5.7% ± 1.7%, respectively). We analyzed the correlation between the percentage of pSTAT5A+ T cells versus (1) CMV‐IgG concentrations versus (2) the percentage of expanded T cells and versus (3) the percentage of initial CMV‐specific T cells. In immunodeficient patients with CARMIL‐2 mutation, CMV‐specific pSTAT5A and T cell proliferation were completely deficient. In conclusion, flow cytometric‐based pSTAT5A assay represents an appropriate tool to quickly identify CMV‐specific T cell proliferation and helps to understand dysfunctions in controlling other pathogens. Flow cytometric‐based pSTAT5A assay may be a useful test in clinical practice and merits further validation in large studies.
- Open Access
- 5 April 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 722
Evaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation
Here we present a simple and sensitive flow cytometric—based assay to assess T cell proliferation. Given the critical role STAT5A phosphorylation in T cell proliferation, we decided to evaluate phosphorylation of STAT5A as an indicator of T cell proliferation. We determined pSTAT5A in T cell treated with either CD3/CD28 or PHA. After stimulation, T cells from adult healthy donors displayed a strong long-lasting phosphorylation of STAT5A, reaching a peak value after 24 h. The median fluorescence intensity (MFI) of pSTAT5A increased from 112 ± 17 to 512 ± 278 (CD3/CD28) (24 h) and to 413 ± 123 (PHA) (24 h), the IL-2 receptor-α (CD25) expression was greatly enhanced and after 72 h T cell proliferation amounted to 52.3 ± 10.3% (CD3/CD28) and to 48.4 ± 9.7% (PHA). Treatment with specific JAK3 and STAT5 inhibitors resulted in a complete blockage of phosphorylation of STAT5A, CD25 expression, and suppression of T cell proliferation. Compared with currently available methods, STAT5A phosphorylation is well-suited to predict T cell proliferation. Moreover, the method presented here is not very time consuming (several hours) and delivers functional information from which conclusions about T cell proliferation can be drawn.
- 5 April 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 722
Open AccessEvaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation
Here we present a simple and sensitive flow cytometric—based assay to assess T cell proliferation. Given the critical role STAT5A phosphorylation in T cell proliferation, we decided to evaluate phosphorylation of STAT5A as an indicator of T cell proliferation. We determined pSTAT5A in T cell treated with either CD3/CD28 or PHA. After stimulation, T cells from adult healthy donors displayed a strong long-lasting phosphorylation of STAT5A, reaching a peak value after 24 h. The median fluorescence intensity (MFI) of pSTAT5A increased from 112 ± 17 to 512 ± 278 (CD3/CD28) (24 h) and to 413 ± 123 (PHA) (24 h), the IL-2 receptor-α (CD25) expression was greatly enhanced and after 72 h T cell proliferation amounted to 52.3 ± 10.3% (CD3/CD28) and to 48.4 ± 9.7% (PHA). Treatment with specific JAK3 and STAT5 inhibitors resulted in a complete blockage of phosphorylation of STAT5A, CD25 expression, and suppression of T cell proliferation. Compared with currently available methods, STAT5A phosphorylation is well-suited to predict T cell proliferation. Moreover, the method presented here is not very time consuming (several hours) and delivers functional information from which conclusions about T cell proliferation can be drawn.
- 1 November 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 140 (5) , 1439-1441.e9
Flow cytometric measurement of STAT1 and STAT3 phosphorylation in CD4+ and CD8+ T cells—clinical applications in primary immunodeficiency diagnostics
- 1 November 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 140 (5) , 1439-1441.e9
Flow cytometric measurement of STAT1 and STAT3 phosphorylation in CD4+ and CD8+ T cells—clinical applications in primary immunodeficiency diagnostics